India First Dengue Vaccine Qdenga TAK-003 Approval April 2026 – DCGI

India recently approved its first dengue vaccine in April 2026, cleared by the Subject Expert Committee (SEC) under the DCGI. Which of the following correctly identifies the vaccine and its approved age group?

Correct Answer: Qdenga (TAK-003) by Takeda; approved for individuals aged 4 to 60 years

India recently approved Takeda's TAK-003 (Qdenga) as its first dengue vaccine, cleared by the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) for individuals aged 4 to 60 years. This marks a historic shift from reactive vector control to a preventive public health strategy against dengue.

Key Features of Qdenga (TAK-003)

• It is a tetravalent dengue vaccine (targets all 4 dengue serotypes: DENV-1 to DENV-4).
• Tested on 28,000+ participants and approved in 40+ countries.
• It is a disease-modifying vaccine, not a transmission-blocking one — reduces clinical severity but does not prevent infection or eliminate outbreaks.
• Unlike Dengvaxia (Sanofi's vaccine), Qdenga does not require prior dengue infection testing, making rollout simpler.

Key Limitations of Qdenga

• Highly effective against DENV-2 (its genetic backbone) but notably lower efficacy against DENV-3 and DENV-4, especially in seronegative individuals.
• India's dengue epidemiology is shifting — DENV-3 is rising (contributing 20–30% of cases), potentially reducing population-level impact.
• Cost concern: Full two-dose course estimated at Rs 6,000–12,000.

Indigenous Pipeline

India is developing 'DengiAll' (by Panacea Biotec and ICMR) aiming for more balanced protection across all four serotypes, potentially available by 2027.

Why Other Options Are Wrong

• DengiAll — Still in development; not yet approved as of 2026.
• Dengvaxia (Sanofi) — Requires prior infection testing and was not the vaccine recently approved in India under this SEC clearance.
• Age group 2 to 18 years only — Incorrect; Qdenga is approved for the broader 4–60 years age group.